Department of Orthopaedics, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
Department of Traditional Chinese Medicine, Affiliated Hospital of Yangzhou University, Yangzhou, People's Republic of China.
Nutr Neurosci. 2024 Sep;27(9):917-933. doi: 10.1080/1028415X.2023.2278867. Epub 2023 Nov 11.
To comprehensively assess the neurologic recovery potential of chondroitinase ABC (ChABC) in rats after spinal cord injury (SCI).
The PubMed, Embase, ScienceDirect, Web of Science, and China National Knowledge Infrastructure databases were searched for animal experiments that evaluated the use of ChABC in the treatment of SCI up to November 2022. Studies reporting neurological function using the Basso, Beattie, and Bresnahan (BBB) scale, as well as assessments of cavity area, lesion area, and glial fibrillary acidic protein (GFAP) levels, were included in the analysis.
A total of 46 studies were ultimately selected for inclusion. The results of the study showed that rats with SCI that received ChABC therapy exhibited a significant improvement in locomotor function after 7 days compared with controls (32 studies, weighted mean difference (WMD) = 0.58, [0.33, 0.83], < 0.00001). Furthermore, the benefits of ChABC therapy were maintained for up to 28 days according to BBB scale. The lesion area was reduced by ChABC (5 studies, WMD = -20.94, [-28.42, -13.46], < 0.00001). Meanwhile, GFAP levels were reduced in the ChABC treatment group (8 studies, WMD = -29.15, [-41.57, -16.72], 0.00001). Cavity area is not statistically significant. The subgroup analysis recommended that a single injection of 10 μL (8 studies, WMD = 2.82, [1.99, 3.65], 0.00001) or 20 U/mL (4 studies, WMD = 2.21, [0.73, 3.70], 0.003) had a better effect on improving the function. The funnel plot of the BBB scale was found to be essentially symmetrical, indicating a low risk of publication bias.
This systematic review and meta-analysis has indicated that ChABC could improve functional recovery in rats after SCI.
全面评估软骨素酶 ABC（ChABC）在脊髓损伤（SCI）后大鼠中的神经恢复潜力。
检索 PubMed、Embase、ScienceDirect、Web of Science 和中国知网数据库，以评估 ChABC 治疗 SCI 的动物实验，截至 2022 年 11 月。纳入分析的研究报告使用 Basso、Beattie 和 Bresnahan（BBB）量表评估神经功能，以及评估空洞面积、病变面积和胶质纤维酸性蛋白（GFAP）水平。
最终共纳入 46 项研究。研究结果表明，与对照组相比，接受 ChABC 治疗的 SCI 大鼠在 7 天后运动功能显著改善（32 项研究，加权均数差（WMD）=0.58，[0.33，0.83]，<0.00001）。此外，根据 BBB 量表，ChABC 治疗的益处可持续至 28 天。ChABC 减少病变面积（5 项研究，WMD=-20.94，[-28.42，-13.46]，<0.00001）。同时，ChABC 治疗组 GFAP 水平降低（8 项研究，WMD=-29.15，[-41.57，-16.72]，0.00001）。空洞面积无统计学意义。亚组分析建议，单次注射 10 μL（8 项研究，WMD=2.82，[1.99，3.65]，<0.00001）或 20 U/mL（4 项研究，WMD=2.21，[0.73，3.70]，0.003）对改善功能效果更好。BBB 量表的漏斗图基本对称，表明发表偏倚风险较低。
本系统评价和荟萃分析表明，ChABC 可改善 SCI 后大鼠的功能恢复。
